$CAPR
CAPRICOR THERAPEUTICS, INC.

2023 Q4 Form 10-Q Financial Statement

#000155837023019065 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $12.09M $6.186M $1.592M
YoY Change 364.93% 288.66%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.429M $3.020M $2.565M
YoY Change 22.72% 17.74% 42.45%
% of Gross Profit
Research & Development $9.940M $10.00M $5.500M
YoY Change 59.51% 81.82% 120.0%
% of Gross Profit
Depreciation & Amortization $307.6K $276.5K $137.0K
YoY Change 60.55% 101.76% 111.73%
% of Gross Profit
Operating Expenses $13.37M $13.05M $8.069M
YoY Change 48.12% 61.73% 87.03%
Operating Profit -$6.865M -$6.478M
YoY Change 5.97% 50.14%
Interest Expense $452.2K $480.0K $106.6K
YoY Change 19.09% 350.11% 584.91%
% of Operating Profit
Other Income/Expense, Net $67.66K $474.0K $106.6K
YoY Change 344.5% -72.14%
Pretax Income -$762.1K -$6.390M -$6.371M
YoY Change -90.13% 0.3% 62.04%
Income Tax
% Of Pretax Income
Net Earnings -$762.1K -$6.391M -$6.371M
YoY Change -90.13% 0.31% 62.04%
Net Earnings / Revenue -6.3% -103.31% -400.3%
Basic Earnings Per Share -$0.25 -$0.26
Diluted Earnings Per Share -$0.02 -$0.25 -$0.26
COMMON SHARES
Basic Shares Outstanding 30.79M 25.78M 24.35M
Diluted Shares Outstanding 25.82M 24.43M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.49M $28.52M $46.61M
YoY Change -4.67% -38.82% 14.14%
Cash & Equivalents $14.69M $8.985M $8.414M
Short-Term Investments $24.79M $19.54M $38.20M
Other Short-Term Assets $995.8K $460.0K $343.7K
YoY Change 8.25% 33.85% 23.22%
Inventory
Prepaid Expenses
Receivables $10.37M $550.0K $547.6K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $50.86M $29.53M $47.50M
YoY Change 18.58% -37.84% 15.03%
LONG-TERM ASSETS
Property, Plant & Equipment $7.611M $5.140M $3.591M
YoY Change 65.88% 43.11% 137.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $268.2K $270.0K $268.2K
YoY Change 0.0% 0.68% -7.11%
Total Long-Term Assets $7.879M $7.625M $6.423M
YoY Change 9.33% 18.71% 256.4%
TOTAL ASSETS
Total Short-Term Assets $50.86M $29.53M $47.50M
Total Long-Term Assets $7.879M $7.625M $6.423M
Total Assets $58.73M $37.15M $53.93M
YoY Change 17.25% -31.11% 25.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.250M $6.790M $3.937M
YoY Change 26.94% 72.49% 31.73%
Accrued Expenses $749.1K $730.0K $697.6K
YoY Change 9.83% 4.65%
Deferred Revenue $24.27M $25.41M $18.60M
YoY Change 34.98% 36.59%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.27M $32.93M $23.19M
YoY Change 32.57% 41.96% 676.18%
LONG-TERM LIABILITIES
Long-Term Debt $3.376M $3.380M $3.376M
YoY Change 0.0% 0.11% 0.0%
Other Long-Term Liabilities $1.487M $2.640M $11.93M
YoY Change -86.9% -77.87%
Total Long-Term Liabilities $4.863M $6.013M $15.31M
YoY Change -66.97% -60.72% 353.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.27M $32.93M $23.19M
Total Long-Term Liabilities $4.863M $6.013M $15.31M
Total Liabilities $36.13M $38.94M $38.50M
YoY Change -5.68% 1.14% 504.94%
SHAREHOLDERS EQUITY
Retained Earnings -$159.4M -$158.6M -$129.4M
YoY Change 16.26% 22.61% 26.98%
Common Stock $181.7M $156.7M $144.7M
YoY Change 22.16% 8.32% 4.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.60M -$1.788M $15.43M
YoY Change
Total Liabilities & Shareholders Equity $58.73M $37.15M $53.93M
YoY Change 17.25% -31.11% 25.12%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$762.1K -$6.391M -$6.371M
YoY Change -90.13% 0.31% 62.04%
Depreciation, Depletion And Amortization $307.6K $276.5K $137.0K
YoY Change 60.55% 101.76% 111.73%
Cash From Operating Activities -$11.59M -$8.790M -$5.686M
YoY Change 67.98% 54.6% 70.33%
INVESTING ACTIVITIES
Capital Expenditures $729.2K $630.0K -$1.099M
YoY Change -40.35% -157.31% 134.77%
Acquisitions
YoY Change
Other Investing Activities -$5.133M $8.350M -$3.077M
YoY Change -180.66% -371.34%
Cash From Investing Activities -$5.863M $7.720M -$4.177M
YoY Change -214.01% -284.84% 791.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 23.17M 220.0K 1.882M
YoY Change 685.44% -88.31% -71.35%
NET CHANGE
Cash From Operating Activities -11.59M -8.790M -5.686M
Cash From Investing Activities -5.863M 7.720M -4.177M
Cash From Financing Activities 23.17M 220.0K 1.882M
Net Change In Cash 5.710M -850.0K -7.980M
YoY Change 380.01% -89.35% -389.02%
FREE CASH FLOW
Cash From Operating Activities -$11.59M -$8.790M -$5.686M
Capital Expenditures $729.2K $630.0K -$1.099M
Free Cash Flow -$12.32M -$9.420M -$4.586M
YoY Change 51.68% 105.39% 59.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25817676
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24431787
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25468880
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24346775
dei Entity Central Index Key
EntityCentralIndexKey
0001133869
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25241402
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25855070
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25855070
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34058
dei Entity Registrant Name
EntityRegistrantName
CAPRICOR THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0363465
dei Entity Address Address Line1
EntityAddressAddressLine1
10865 Road to the Cure, Suite 150, San Diego
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
727-1755
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CAPR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30792869
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8984667
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9603242
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19536805
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
31818020
CY2023Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
547580
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
547580
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
458417
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
919892
CY2023Q3 us-gaap Assets Current
AssetsCurrent
29527469
CY2022Q4 us-gaap Assets Current
AssetsCurrent
42888734
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5139680
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4588030
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2217009
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2349974
CY2023Q3 us-gaap Other Assets
OtherAssets
268172
CY2022Q4 us-gaap Other Assets
OtherAssets
268172
CY2023Q3 us-gaap Assets
Assets
37152330
CY2022Q4 us-gaap Assets
Assets
50094910
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6771772
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4834683
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
20178
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
89234
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
729567
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
682039
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
25405084
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
17980599
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
32926601
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23586555
CY2023Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1683656
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1878070
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
953470
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
9467932
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6013385
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
14722261
CY2023Q3 us-gaap Liabilities
Liabilities
38939986
CY2022Q4 us-gaap Liabilities
Liabilities
38308816
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25855070
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25241402
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
25855
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
25241
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
156678545
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
148735420
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
113208
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
105244
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-158605264
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137079811
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1787656
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11786094
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37152330
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50094910
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6185814
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1591566
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13089977
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1591566
CY2023Q3 us-gaap Revenues
Revenues
6185814
CY2022Q3 us-gaap Revenues
Revenues
1591566
us-gaap Revenues
Revenues
13089977
us-gaap Revenues
Revenues
1591566
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10028964
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5504356
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26507872
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15585143
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3021450
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1618712
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
57679
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
84707
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7366579
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2564960
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9378672
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7637461
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
13050414
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
8069316
us-gaap Operating Expenses
OperatingExpenses
35886544
us-gaap Operating Expenses
OperatingExpenses
23222604
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6864600
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6477750
us-gaap Operating Income Loss
OperatingIncomeLoss
-22796567
us-gaap Operating Income Loss
OperatingIncomeLoss
-21631038
us-gaap Other Income
OtherIncome
190582
CY2023Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
479380
CY2022Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
106635
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1276502
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
141836
CY2023Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-5388
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-5388
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
473992
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
106635
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1271114
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
332418
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6390608
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6371115
us-gaap Net Income Loss
NetIncomeLoss
-21525453
us-gaap Net Income Loss
NetIncomeLoss
-21298620
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-66485
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
99637
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7964
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
122467
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6457093
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6271478
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21517489
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21176153
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25817676
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24431787
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25468880
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24346775
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11786094
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2194784
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3895
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10258
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7768266
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6206249
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2130395
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2731163
capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
565255
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
221081
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1717193
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-66485
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6390608
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1787656
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31367966
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1065329
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27465
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7818094
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
24642666
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1157904
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15006
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22830
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7109411
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
18728995
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1880324
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1087133
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1518
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
99637
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6371115
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
15426492
us-gaap Profit Loss
ProfitLoss
-21525453
us-gaap Profit Loss
ProfitLoss
-21298620
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-5388
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
761274
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
341529
us-gaap Share Based Compensation
ShareBasedCompensation
5530689
us-gaap Share Based Compensation
ShareBasedCompensation
3310366
capr Noncash Lease Expenses
NoncashLeaseExpenses
-13921
capr Noncash Lease Expenses
NoncashLeaseExpenses
168254
capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
155830
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-461475
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-816253
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-7550
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1937089
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
735985
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-69057
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-515232
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1089977
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
28408434
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14002493
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11818689
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
72665821
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
82175353
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
84955000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
44097961
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
753056
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1306199
capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
831032
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10970868
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40214623
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2351476
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1880324
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
61574
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
43989
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2413050
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1924313
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-618575
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-26471621
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9603242
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34885274
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8984667
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8413653
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
28500000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
41400000
CY2020Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191199
CY2023Q3 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
547580
CY2023Q3 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191463
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p>
CY2023Q3 us-gaap Depreciation
Depreciation
276471
CY2022Q3 us-gaap Depreciation
Depreciation
137028
us-gaap Depreciation
Depreciation
761274
us-gaap Depreciation
Depreciation
341529
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7040521
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5769655
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1900841
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1181625
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5139680
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4588030
capr Grant Income
GrantIncome
0
CY2022Q3 capr Grant Income
GrantIncome
0
capr Grant Income
GrantIncome
0
CY2023Q3 capr Grant Income
GrantIncome
0
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10000000.0
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5500000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26500000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15600000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6500000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6300000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21500000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21200000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8303253
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8303253
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6059552
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6059552
CY2023Q3 capr Amortized Cost Of Marketable Securities
AmortizedCostOfMarketableSecurities
19423597
CY2022Q4 capr Amortized Cost Of Marketable Securities
AmortizedCostOfMarketableSecurities
31712777
capr Commission Rate On Sale Price Per Share
CommissionRateOnSalePricePerShare
0.030
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25855070
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2022Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2023Q3 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
capr Share Based Compensation Number Of Plans
ShareBasedCompensationNumberOfPlans
5
CY2021Q2 capr Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Annual Increase In Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInNumberOfSharesAuthorized
0.05
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1264429
capr Minimum Limit Of Fair Market Value To Be Treated As Non Statutory Stock
MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock
100000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.93
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.41
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.88
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.045
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.015
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.039
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1717193
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1087133
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5530689
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3310366
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
14400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2023Q3 capr Number Of Financial Institutions
NumberOfFinancialInstitutions
3
CY2023Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2023Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
28300000
CY2023Q4 capr Lessee Operating Lease Base Lease Rent Per Month
LesseeOperatingLeaseBaseLeaseRentPerMonth
58409
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
219952
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
886672
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
910106
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
676908
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2693638
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
280415
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2413223
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
729567
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1683656
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2413223
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y11M23D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0724
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2200000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2400000
capr Severance Package To Be Paid For Period Of Base Salary
SeverancePackageToBePaidForPeriodOfBaseSalary
P6M
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
20178
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
89234

Files In Submission

Name View Source Status
capr-20230930_cal.xml Edgar Link unprocessable
0001558370-23-019065-index-headers.html Edgar Link pending
0001558370-23-019065-index.html Edgar Link pending
0001558370-23-019065.txt Edgar Link pending
0001558370-23-019065-xbrl.zip Edgar Link pending
capr-20230930.xsd Edgar Link pending
capr-20230930x10q.htm Edgar Link pending
capr-20230930xex31d1.htm Edgar Link pending
capr-20230930xex31d2.htm Edgar Link pending
capr-20230930xex32d1.htm Edgar Link pending
capr-20230930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
capr-20230930_def.xml Edgar Link unprocessable
capr-20230930_lab.xml Edgar Link unprocessable
capr-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
capr-20230930x10q_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending